News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ngm Biopharmaceuticals Inc
(NQ:
NGM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.550 (545)
Ask (Size)
1.610 (1)
Prev. Close
1.540
Today's Range
N/A - N/A
52wk Range
0.6002 - 2.855
Shares Outstanding
78,049,340
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NGM Bio Announces Closing of Tender Offer
April 05, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
March 19, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Performance
More News
Read More
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
March 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Looking Into NGM Biopharmaceuticals's Recent Short Interest
January 19, 2024
Via
Benzinga
Why NGM Biopharmaceuticals Stock Is Blasting Higher
January 02, 2024
Via
Benzinga
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
February 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Via
Benzinga
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 26, 2024
Via
Benzinga
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
February 26, 2024
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT)
February 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
February 26, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 09, 2024
Via
Benzinga
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
January 09, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 29, 2023
Via
Benzinga
B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know
November 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 13, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in Upcoming Investor Conferences
November 07, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close